Premium
Elevated urinary orosomucoid excretion as a novel biomarker in Crohn’s disease
Author(s) -
Szirmay Balázs,
Tárnok András,
Sarlós Patrícia,
Szigeti Nóra,
Ludány Andrea,
Kustán Péter,
HorváthSzalai Zoltán,
Miseta Attila,
Kőszegi Tamás
Publication year - 2019
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13054
Subject(s) - orosomucoid , urinary system , urine , medicine , gastroenterology , crohn's disease , creatinine , inflammatory bowel disease , biomarker , excretion , crohn disease , disease , chemistry , biochemistry , glycoprotein
Abstract Background Laboratory markers are essential tools in the follow‐up of patients with Crohn's disease (CD). Our aim was to investigate urinary concentrations of orosomucoid in relation to the inflammatory activity of CD and to compare it with clinical indices and conventional laboratory parameters. Materials and methods Blood and urine samples of 86 patients (55 adults and 31 children) with CD and 68 healthy individuals (38 adults and 30 children) as controls were analysed. Patients were categorized according to their clinical scores (Harvey‐Bradshaw Index [HBI] or Pediatric Crohn's Disease Activity Index [PCDAI]). Urinary orosomucoid (u‐ORM) was determined by automated immune turbidimetric assay, and values were referred to urinary creatinine (u‐ORM/u‐CREAT, mg/mmol). Results U‐ORM/u‐CREAT values were seven times higher in children with active CD (0.50 vs 0.07 mg/mmol, P < 0.001) and two times higher in adults (0.32 vs 0.14 mg/mmol, P = 0.01) compared with patients with inactive disease. U‐ORM/u‐CREAT showed good correlation with conventional inflammatory markers (hs‐CRP, serum ORM; P < 0.01) and activity indices (HBI, P = 0.018; PCDAI, P < 0.001). U‐ORM/u‐CREAT had similar discriminative performance to hs‐CRP and serum ORM in the differentiation of active from inactive paediatric CD patients. Conclusions Our findings suggest that u‐ORM/u‐CREAT might serve as a valuable additional marker in the follow‐up of CD patients, especially in children for whom the non‐invasive sampling is a further advantage.